Mavacamten: Real-World Experience from 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program
Background: Mavacamten is the only cardiac myosin inhibitor approved by the US FDA for
treatment of symptomatic New York Heart Association class II-III obstructive hypertrophic …
treatment of symptomatic New York Heart Association class II-III obstructive hypertrophic …